The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab
Overall, the economic impact of treating all patients with VO led to 10-year cumulative savings of CAD 169,341 and CAD 293,731 per patient, without and with TP53 aberration, respectively. These savings are mainly due to reductions in treatment costs associated with fixed treatment duration.
Authors
- Jean Lachaîne (ORCID: https://orcid.org/0000-0002-0791-2518)
- Dipti Tankala (ORCID: https://orcid.org/0009-0008-4849-2442)
- Kimberly Guinan (ORCID: https://orcid.org/0000-0001-5245-1178)
- Versha Banerji (ORCID: https://orcid.org/0000-0002-7415-8818)
- Nancy Paul Roc
- Christopher Hillis
- Sarah-Jane Bull
- Beenish S. Manzoor (ORCID: https://orcid.org/0000-0002-0329-3465)
- Stéphane Barakat
- Karine Mathurin
Institutions
- AbbVie (United States) (US)
- CancerCare Manitoba (CA)
- University of Manitoba (CA)
- Université de Montréal (CA)
- McMaster University (CA)
Publication Details
- Journal
- Cancers
- Published
- 2024-09-17
- DOI
- https://doi.org/10.3390/cancers16183182
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.44
Funders
- AbbVie Canada